Abstract
Combined hyperlipidaemia and the presence of small and dense LDL particles in the circulation are associated with an increased risk of myocardial infarction.
The effect of pravastatin on plasma lipoproteins and on LDL size has been evaluated in a single-blind, randomised, placebo-controlled study in 24 patients with combined hyperlipidaemia; 12 patients on pravastatin and 12 on placebo.
After 16 weeks on pravastatin, plasma total (−15%) and LDL (−23%) cholesterol and apo B (−13%) levels were significantly reduced and apo AI (+6%) had increased. LDL size (measured by gradient gel electrophoresis) had not changed. No adverse effect was observed.
The study suggests that, in combined hyperlipidaemia, LDL size is not affected by variation in LDL receptor activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52: 1544–1568
Hunninghake DB (1992) HMG CoA reductase inhibitors. Curr Opin Lipidol 3: 22–28
Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33: 1569–1582
Vega GL, Grundy SM (1990) Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA 264: 2759–2763
Ojala JP, Helve E, Tikkanen MJ (1990) Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study. Cardiology 77 [Suppl 4]: 39–49
Yoshino G, Kazumi T, Iwai M, Iwatani I, Matsuba K, Kasama T, Matsushita M, Otsuki M, Baba S (1988) Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 71: 95–101
East C, Bilheimer DW, Grundy SM (1988) Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 109: 25–32
Vega GL, Grundy SM (1990) Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 150: 1313–1319
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988) Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 1917–1921
Lipid research clinics program (1982) Manual of laboratory operations. Lipid and lipoprotein analysis, 2nd edn. US Department of Health and Human Service, Washington, DC, pp 63–77
Roschlau VP, Bernt E, Gruber W (1974) Enzymatische Bestimmung des Gesamtcholesterins im Serum. Klin Chem Klin Biochem 12: 403–407
Wahlefeld AW (1976) Triglycerides. Determination after enzymatic hydrolysis. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Academic Press, New York, pp 1831–1835
Nichols AV, Krauss RM, Musliner TA (1986) Nondenaturing polyacrylamide gradient gel electrophoresis. In: Segrest JP, Albers JJ (eds) Methods in enzymology. Academic Press, New York, Orlando, pp 417–431
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol-reagent. J Biol Chem 193: 265–275
Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 227: 81–94
Vega GL, Grundy SM (1991) Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med 230: 341–349
Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of apo B-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 31: 567–582
Grundy SM, Chait A, Brunzell JD (1987) Familial combined hyperlipidemia workshop. Arteriosclerosis 7: 203–207
Babirak SP, Brown BG, Brunzell JD (1992) Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 12: 1176–1183
Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989) HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80: 1313–1319
Slunga L, Johnson O, Dahlen GH (1992) Changes in Lp(a) lipoprotein levels during treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 43: 369–373
Nishina PM, Johnson JP, Naggert JK, Krauss RM (1992) Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 89: 708–712
Superko HR, Krauss RM (1992) Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95: 69–76
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zambon, S., Cortella, A., Sartore, G. et al. Pravastatin treatment in combined hyperlipidaemia. Eur J Clin Pharmacol 46, 221–224 (1994). https://doi.org/10.1007/BF00192552
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00192552